The Citizens Commission on Human Rights (CCHR) is urging consumers to read the labeling of psychotropic prescription drugs for warnings about suicide, aggression, and homicidal ideation, and to ask their prescribing physicians to explain these risks, even when they are listed as rare. The call follows news reports of violent crimes in which some individuals were reported to have been taking, or withdrawing from, prescribed antidepressants, stimulants, or other psychiatric drugs with documented side effects of aggression, homicidal, and suicidal ideation.
CCHR says such reports underscore a broader consumer issue: patients should know what regulators and manufacturers disclose about these drugs, and prescribers should ensure they are fully aware of potential risks. The organization's decades-long campaign has drawn attention to reports of agitation, aggression, suicidal behavior, and homicidal thoughts associated with some psychotropic drugs, leading U.S. and foreign regulators to require warnings or adverse-reaction information in labeling.
Jan Eastgate, president of CCHR International, emphasizes the gap between a warning in a package insert and meaningful informed consent. "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient," she says. "Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk."
The issue of psychiatrists' responsibility is being debated in courtrooms and professional circles. A recent article in Psychiatric Times, titled "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?" discusses a high-profile murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior. The journal noted that "a good portion of the public and the media appear to support the defense theory" and that the litigation "places psychiatrists and other mental health providers under scrutiny."
When prescribed drugs are alleged to have induced violent behavior, one legal doctrine is involuntary intoxication. Its applicability depends on the facts and governing law, including whether the drug was taken as prescribed and whether the person knew or reasonably could have known of the particular intoxicating or behavioral effect.
CCHR's compilation of international regulatory agency warnings identifies 57 warnings or safety notices since 2004 involving violence, aggression, or hostility, compared with five in 2004—a 1,040% increase. Thirteen of those notices specifically reference homicidal ideation or thoughts of harming others. Examples include the 2005 addition of homicidal ideation to venlafaxine labeling, the 2009 FDA boxed warning for bupropion citing hostility and homicidal ideation, and the 2023 class-wide warning for CNS stimulants about suicidal or homicidal ideation with misuse.
The central issue, according to CCHR, is that printing a warning does not ensure a patient has seen it, understood it, or discussed it with a physician. This concern has entered public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents, and CCHR has called for similar laws in every state.
Eastgate stresses that while not all individuals taking a psychotropic drug will become violent or suicidal, they should read warnings and ask questions before agreeing to treatment. "Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent."
Ultimately, CCHR says the issue is not whether every patient will experience these reactions, but whether patients are adequately informed when regulators have identified potentially serious behavioral adverse effects, and whether prescribers are held accountable for ensuring patients are warned. Patients should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be done under medical supervision. CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, maintains that transparent disclosure of known risks and prescriber accountability are fundamental to meaningful informed consent.
